Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics (Keta4SI)
Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics: a Pilot Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Karly Stillwell
- Phone Number: 3691 (604) 875-2345
- Email: kstillwell@bcchr.ca
Study Contact Backup
- Name: Tatsuma Hind, BSc
- Email: txhind@student.ubc.ca
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3N1
- BC Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
The study will enroll children and adolescents presenting with SI in the paediatric ED.
Inclusion Criteria:
- 10 to 17 years of age
- Respond "yes" to either question 1 (Passive Ideation) or 2 (Active Ideation) on the C-SSRS
- Respond "yes" to either questions 3 (Method), 4 (Intent), or 5 (Plan) on the C-SSRS
- Deemed acceptable and appropriate for admission to the on-site Child and Adolescent Psychiatry Emergency (CAPE) unit by a pediatric psychiatrist
- Successful completion of Capacity to Assent.
- Normal vital signs for age and a normal neurological exam (no focal deficits or abnormalities), as per attending clinician
Exclusion Criteria:
- History of benzodiazepine or ketamine use in the past 3 months (ample wash out period)
- Lifetime history of ketamine or benzodiazepine use disorder
- Previous diagnosis of schizophrenia or active psychosis as per the treating physician
- Lifetime history of schizoaffective disorder
- Current hypomania, mania, mixed state
- Clinically unstable, requires resuscitation or admission to a medical ward for stabilizing therapy (i.e., intensive care unit.)
- History of cerebrovascular accident, uncontrolled seizure disorder, increased intracranial pressure
- Uncontrolled hypertension, low or labile blood pressure, severe cardiac decompensation
- Moderate to severe hepatic/renal impairment
- Intoxicated or delirious
- Suspected or confirmed pregnancy or women who are breastfeeding
- Known allergy or sensitivity to ketamine and/or midazolam or any component in the formulation.
- Neuro-cognitive impairment that precludes informed consent, assent, or ability to self-report pain and satisfaction
- Inability to understand spoken and/or written English without the use of an interpreter
- Previous enrollment in this study
- No parent/guardian present.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intravenous ketamine
Infusion of 0.5 mg/kg of ketamine, at maximum dose of 40 mg, over 40 minutes.
|
A 10 mg/mL solution of ketamine will be infused over a 40 minute period at a dose of 0.05mg/kg.
|
|
Active Comparator: Intravenous midazolam
Infusion of 0.03 mg/kg of midazolam, at maximum dose of 2 mg, over 40 minutes.
|
A 5 mg/mL solution of midazolam will be infused over a 40 minute period at a dose of 0.02 mg/kg.
|
|
Placebo Comparator: Intravenous saline
Infusion of 0.9% saline over 40 minutes.
|
A 0.9% normal saline solution will be infused over a 40 minute period.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Columbia Suicide Severity Rating Scale (C-SSRS)
Time Frame: 90 minutes post infusion
|
The CSSR-S is 6-point scale that measures SI severity via clinical interviews, ranging from 1 (wish to be dead) to 5 (suicidal intent with plan).
Adolescents who deny any SI receive a 0. The distribution of "yes" responses on questions 3, 4, or 5 will be assessed from baseline.
Higher scores indicate greater SI severity.
|
90 minutes post infusion
|
|
Montgomery-Åsberg Depression Rating Scale (MADRS)
Time Frame: 90 minutes post infusion
|
The MADRS is a 10-item, 6-point scale that screens for depressive symptoms in adults via clinical interviews.
A self-reported version (MADRS-self assessment) which has been validated in adolescents will be used, but only the final item that is specific to SI (item 10) will be asked.
The distribution of scores from 0 to 6 will be assessed from baseline.
Higher scores indicate greater SI severity.
|
90 minutes post infusion
|
|
Pragmatic questionnaire
Time Frame: 90 minutes post infusion
|
The pragmatic questionnaire is a brief, one sentence question designed to assess change in SI.
Participants will be asked "How suicidal do you feel on a scale of 0 to 10?".
The distribution of scores from 0 to 10 will be assessed from baseline.
Higher scores indicate greater SI severity.
|
90 minutes post infusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Columbia Suicide Severity Rating Scale (C-SSRS)
Time Frame: 24 hours
|
The CSSR-S is 6-point scale that measures SI severity via clinical interviews, ranging from 1 (wish to be dead) to 5 (suicidal intent with plan).
Adolescents who deny any SI receive a 0. The distribution of "yes" responses on questions 3, 4, or 5 will be assessed from baseline.
Higher scores indicate greater SI severity.
|
24 hours
|
|
Montgomery-Åsberg Depression Rating Scale (MADRS)
Time Frame: 24 hours, 7-, 14-, 21-, and 28 days
|
The MADRS is a 10-item, 6-point scale that screens for depressive symptoms in adults via clinical interviews.
A self-reported version (MADRS-self assessment) which has been validated in adolescents will be used, but only the final item that is specific to SI (item 10) will be asked.
The distribution of scores from 0 to 6 will be assessed from baseline.
Higher scores indicate greater SI severity.
|
24 hours, 7-, 14-, 21-, and 28 days
|
|
Pragmatic questionnaire
Time Frame: 24 hours, 7-, 14-, 21-, and 28 days
|
The pragmatic questionnaire is a brief, one sentence question designed to assess change in SI.
Participants will be asked "How suicidal do you feel on a scale of 0 to 10?".
The distribution of scores from 0 to 10 will be assessed from baseline.
Higher scores indicate greater SI severity.
|
24 hours, 7-, 14-, 21-, and 28 days
|
|
Blinding assessment
Time Frame: 90 minutes post infusion
|
The proportion of participants and research personnel that correctly identify treatment arm allocation.
|
90 minutes post infusion
|
|
Enrolment rate
Time Frame: 28-days
|
Proportion of eligible patients that consent to participate, and proportion of participants that are lost to follow-up at 7-, 14-, 21-, and 28-days.
|
28-days
|
|
Demographics
Time Frame: 28-days
|
Demographics of eligible patients who decline to participate in the study.
|
28-days
|
|
Drug reactions
Time Frame: 28-days
|
Incidence and frequency of side effects and adverse events.
|
28-days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Quynh Doan, PhD MHSc MD, University of British Columbia
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Self-Injurious Behavior
- Suicide
- Suicidal Ideation
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Anesthetics
- Central Nervous System Depressants
- Sensory System Agents
- Analgesics
- Neurotransmitter Agents
- Adjuvants, Anesthesia
- Hypnotics and Sedatives
- Anti-Anxiety Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anesthetics, Intravenous
- Anesthetics, General
- GABA Modulators
- GABA Agents
- Excitatory Amino Acid Agents
- Anesthetics, Dissociative
- Excitatory Amino Acid Antagonists
- Midazolam
- Ketamine
- Pharmaceutical Solutions
Other Study ID Numbers
Other Study ID Numbers
- H21-01433
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.